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Whole-Genome Sequencing and
Disability in the NICU: Exploring
Practical and Ethical Challenges
Michael J. Deem, PhD

Clinical whole-genome sequencing (WGS) promises to deliver faster diagnoses and lead to
better management of care in the NICU. However,several disability rights advocates have
expressed concern that clinical use of genetic technologies may reinforce and perpetuate
stigmatization of and discrimination against disabled persons in medical and social
contexts. There is growing need, then, for clinicians and bioethicists to consider how the
clinical use of WGS in the newborn period might exacerbate such harms to persons with
disabilities. This article explores ways to extend these concerns to clinical WGS in neonatal
care. By considering these perspectives during the early phases of expanded use of WGS in
the NICU, this article encourages clinicians and bioethicists to continue to reflect on ways to
attend to the concerns of disability rights advocates, foster trust and cooperation between
the medical and disability communities, and forestall some of the social harms clinical WGS
might cause to persons with disabilities and their families.
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SUPPLEMENT ARTICLE

Whole-genome sequencing (WGS)
has emerged as a powerful diagnostic
tool for uncovering previously
unknown gene-disease associations
and establishing the genetic
etiology of undiagnosed conditions
in individual patients.1–5 The time
and monetary costs required to
sequence an entire human genome
continue to decrease, making the
implementation of WGS in clinical
practice increasingly feasible. Many
researchers and clinicians believe
that clinical WGS will lead to faster
diagnoses and better management of
care.

WGS also gives rise to challenging
practical and ethical questions.
This is especially the case with
respect to the increasing use of
WGS for therapeutic guidance in the
NICU.6–8 Families and health care
professionals frequently face difficult
decisions about the appropriate
clinical management of neonates
who have profound disabilities,
especially when clinicians encounter
difficulties in diagnosing these
conditions. Sometimes WGS can
provide a genetic diagnosis for
these neonates and lead to a more
precise prognosis for survival and
outcomes of available treatment
options. However, several disability
rights advocates have expressed
concern that the clinical use of
genetic technologies may reinforce
and perpetuate stigmatization of
and discrimination against disabled
persons in medical and social
contexts.9–11 There is growing need,
then, for clinicians and bioethicists
to consider how the clinical use of
WGS in the newborn period might
exacerbate these potential harms to
persons with disabilities.
This article explores ways to extend
some of the concerns of disability
rights advocates to clinical WGS in
neonatal care. By considering these
concerns during the early phases of
expanded use of WGS in the NICU,
I hope to encourage clinicians and
bioethicists to continue reflecting on
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ways to foster trust and cooperation
between the medical and disability
communities, and to forestall some
of the social harms clinical WGS may
cause to persons with disabilities and
their families.

Disability Critiques of Prenatal
Genetic Testing
The offer of prenatal genetic
testing (PGT) during pregnancy
is becoming a standard aspect of
perinatal care. With the advent of
noninvasive modes of testing, such as
MaterniT21,12 NIFTY,13 and direct-toconsumer tests that can also provide
information about fetal gender in
the early stages of pregnancy, we
can expect even greater uptake
of PGT in the near term. PGT’s
primary function is the identification
of genetic and chromosomal
abnormalities in developing fetuses,
and it is widely held that this
information can augment patient
autonomy and reproductive choice.
Although many laud the apparent
benefits of PGT, this testing is also
an area of deep contention between
providers of genetic services and
many disability rights advocates.14,15

Some disability rights advocates
maintain that the routine use of
PGT has had negative effects on the
disability community. It has, they
contend, led to further stigmatization
of and discrimination against persons
with certain kinds of disabilities.
Although the details of disability
rights critiques of PGT vary, 2
common themes emerge. One theme
is that the offer of PGT to pregnant
women is a tacit recommendation
that pregnancies should be
terminated if the fetus is diagnosed
with certain genetic disorders.16–18
On this view, the targeting of specific
disabilities has the consequence
of separating and labeling some
fetuses and pregnancies as
“abnormal,” thereby increasing the
likelihood of social stigmatization
and marginalization of persons who

are born with these disabilities. A
second theme is that decisions to
terminate pregnancy after detection
of fetal abnormality express a
negative and hurtful message about
disability and the value of persons
living with prenatally diagnosable
conditions.19,20 Selective termination
for disability, it is argued, sends
a twofold message to disabled
persons. First, it expresses a view
of persons with genetic disorders
as reducible to a single undesirable
trait. Second, it suggests that it would
have been better had their birth been
prevented.

Several philosophers and bioethicists
have engaged in important
debates over the philosophical
merits of disability critiques of
PGT.21–24 Rather than rehearse
those arguments here, it is worth
considering the extent to which the
historically close association between
PGT and selective termination for
disability has affected persons living
with disabilities and their families.
Many families of children with
prenatally diagnosable conditions
report feeling subject to negative
social attitudes on account of
their decisions not to terminate
pregnancy. The remarks of Patricia
Bauer, a mother of a child with Down
syndrome, are representative of
these families’ concerns:
More and more these days, we parents
of people with genetic anomalies are
being called to account by the well-tested
public for our reproductive choices and
our lives. . . . “Didn’t you have the test
[emphasis added]?” someone asks, eyeing
our child’s face with a raised eyebrow
that seems to betray surprise, curiosity,
disapproval. . . . Wouldn’t it have been
better, we hear the questioners asking, if
this person didn’t exist?25

The influence of social expectations
of selective termination after PGT
can affect the perspectives of health
care professionals and bioethicists
as well. Dena Davis, for example,
attests to the impact of these
social expectations on her intuitive
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response to children with prenatally
diagnosable disabilities:

In my own mind I can discern a subtle
shift in the way in which I view people
with certain anomalies. Twenty years
ago, seeing a woman in the supermarket
with a child who has Down syndrome,
my immediate reactions were sympathy
and a sense that that woman could be me.
Now that testing for Down syndrome is
virtually universal in the United States,
when I see such a mother and child I am
more likely to wonder why she didn't get
tested.26

Disconnecting Diagnosis and
Decision
What explains the pervasiveness
of the social perception that a
decision for selective termination
should follow a positive PGT result?
The circumstances surrounding
the initial introduction of PGT into
perinatal care may provide a partial
answer. When PGT was originally
presented to the medical community,
some clinicians touted it as both a
diagnostic test and as a determinant
of a specific medical outcome in
the event of a positive test result.
Strong emphasis was placed on PGT’s
value as an aid for decisions about
whether to terminate pregnancies
in which genetic or chromosomal
abnormalities are detected.27
The early association of PGT with
selective termination reverberates
in genetic counseling today.28–30
Genetic counselors have recognized
the negative social consequences
of the historical association of PGT
and selective termination, and many
have initiated important efforts to
recover lost trust between clinical
genetics practice and the disability
community.31,32
Now, the traditional connection
between PGT and selective
termination does not imply that
medical genetics is solely responsible
for social harms to the disability
community brought in the wake of
PGT. An argument could be made
that social biases and discriminatory
attitudes toward disability existed

before the routine use of PGT, and
that the early medical association
between PGT and selective
termination simply reflected those
prevailing public attitudes toward
disability. Whatever the case may
be, it is important to consider
what clinicians and bioethicists
who advocate for the expansion of
clinical WGS can learn from PGT and
selective termination. But before we
can answer this question, we need
to ask what, if any, analog there
is between WGS of newborns, on
the one hand, and PGT followed by
selective termination, on the other.
A good candidate is the initiation of
palliative care in newborns after a
molecular diagnosis via WGS. Like
the various modes of PGT, WGS
is a powerful diagnostic tool, and
the data it generates will likely
have a significant effect on the
management of patient care in the
NICU. Just as the early association
of PGT with selective termination
played a significant role in shaping
public attitudes toward prenatally
diagnosable disability, the social
impact that routine use of WGS in
the NICU will have on the disability
community will turn, in part,
on the way in which health care
professionals portray and promote
its clinical function.

In contrast to the initial
implementation of PGT, the current
expansion of WGS has not yet been
closely linked to a redirection toward
palliative care after molecular
diagnosis. In the medical literature,
however, there are discussions of
palliative care being one possible
option after a molecular diagnosis
by WGS. There also is discussion
of particular cases in which WGS
may have factored in decisions to
redirect management of care toward
palliation.6,33 Although these early
discussions do not tightly link WGS
with palliative care, we should
nonetheless consider carefully how
the portrayal of diagnostic WGS
as a tool for determining whether

to withdraw aggressive medical
interventions and initiate palliative
care in newborns might reinforce
negative social attitudes toward
disability.

One must, of course, delineate cases
in which introducing palliative
care as an option to families after
receiving a molecular diagnosis via
WGS is appropriate. For example,
there may be cases in which a
newborn is suffering unremitting
pain, and additional cure-oriented
interventions exacerbate that
suffering or have a very low
probability of improving the outcome
for that child. WGS may provide a
definitive or likely diagnosis where
conventional clinical diagnostic
methods failed, providing families
with the knowledge and closure they
need to accept their child’s terminal
prognosis. The ability to explain to
families the genetic etiology of a
terminal condition may aid health
care professionals in providing
compassionate counseling and
additional support to families, where
uncertainty would have otherwise
placed obstacles.
How, then, can we portray WGS in
the NICU in a way that is conscious
of the concerns of the disability
community? We should be careful
to portray clinical WGS for what it
really is: a diagnostic tool that has
the potential to play an important
informative role in determining
proper clinical management of
acutely ill newborns. Again, a useful
comparison can be made with
PGT. Despite the fact that PGT is
frequently used today for several
other ends, for example, to plan
perinatal interventions, to initiate
perinatal palliative care, and to
help prepare families emotionally
and psychologically for caring for a
child with diagnosable disabilities,
selective termination has largely
crowded these benefits out from
public perception. WGS may impact
individual patient care in a number
of possible ways, including, but
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hardly limited to, the initiating of
palliative care where appropriate.
When our general discussions of WGS
expressly link it to palliative care,
we risk similarly obscuring several
potential benefits WGS delivers
to individualized care. Moreover,
by stressing that WGS might be a
cost-effective way of moving more
quickly to comfort care, health care
professionals might reinforce the
idea that disability is a costly drain
on medical and societal resources.
The medical portrayal and social
reception of PGT, then, provides
us with important lessons for
presenting to the public the rapid
advance of diagnostic WGS in the
NICU. We should not only be cautious
with respect to how we characterize
the benefits of WGS, but also consider
how associating WGS in the NICU
with redirection to palliative care
might implicitly communicate a
harmful message to disabled persons
and their families, potentially fueling
distrust toward the use of genetic
technologies in clinical care.

Misinformation and
Informational Opacity
The preceding discussion of disability
critiques of PGT connects to another
major concern that disability rights
advocates express regarding prenatal
screening. Some have argued that
the routine use of screening in
perinatal care largely depends on
misinformation about the lives
and experiences of children with
disabilities and their families.34–36
This misinformationis thought to be
rooted in the widely held assumption
that life with profound disability
is inherently tragic, laden with
relentless suffering and frustration
for both the disabled child and the
family. Routine testing of fetuses for
genetic and chromosomal anomalies
takes place, it is argued, because
of the persistent belief that a life
with the associated diseases and
disabilities either is not worth living
S50

or places an extraordinary burden on
caretakers.
This concern is not without
grounds. Empirical studies of
parents’ perspectives of prenatal
screening suggest that information
provision to families about the
capacity and accuracy of detection
of fetal abnormalities remains
inadequate, and some families of
children with prenatally diagnosed
disabilities report that genetic
counseling provided little or no
information about the quality of life
for children with disabilities and
their families.28,37–40 Concern that
misinformation about disability
erodes responsible medical decisionmaking arises not only from routine
prenatal screening. Indeed, disability
rights advocates point to cases in
neonatology, pediatrics, and endof-life care in which assumptions
about the quality of life of persons
with profound disabilities may be
responsible, at least in part, for
families’ and clinicians’ decisions
to discontinue life-sustaining
interventions.41

The expansion of WGS in the NICU
almost certainly will compound the
difficulties involved with ensuring
that decisions about the clinical
management of newborns with
profound disabilities are informed
and responsible. WGS yields an
immense amount of data that must be
analyzed and interpreted to provide
potential benefits to clinical care.
The sheer volume of raw genomic
data presents tremendous challenges
to the effective communication of
their potential clinical significance
to clinicians and to the clinical
counseling of families of ill neonates.
Here I will focus on 3 such challenges,
all of which involve informational
opacity in the interpretation and
transmission of genomic information.
In one of the first explorations of the
implications of routine use of WGS
in the NICU, Stephen Kingsmore
and Carol Saunders lamented the
lack of a clinical-grade general

database of identified variantdisease associations, which analysts
and clinicians could refer to after
performing WGS on ill newborns.42 A
half-decade later, no such a database
is available, although there is reason
for optimism. ClinVar, for example,
is a publicly accessible database
that aggregates reported data on
variant-disease associations.43
This aggregation of data, however,
depends on the initiative of clinical
laboratories to report novel findings
and interpretations, and the accuracy
of these data may vary widely. Until
there is a clinical-grade general
database available to analysts
and clinicians, as well as broadly
accepted methods for standardizing
interpretations of sequence variants,
it will remain a challenge to ensure
that clinicians are sufficiently familiar
with and have ready access to the
most recent emerging data about
variant-disease associations and their
clinical significance.
The absence of a general database
and accepted standards of
interpretation leads to a second
complication in providing
appropriate post-WGS counseling
to families. Before it can provide
guidance to decision-making about
the clinical management of ill
newborns, the diagnostic information
that WGS yields first passes through
multiple levels of interpretation.
Genomic data are initially analyzed
and interpreted by genetic analysts
and clinical laboratories, with
one possible outcome being the
identification of variants that are
clinically actionable. Discrepant
interpretations of the clinical
significance of identified sequence
variants, however, are common, even
when it comes to well-studied genes
and genome regions.44,45 Interpretive
discrepancies at this level can
undermine high-fidelity transmission
of information about the clinical
utility of sequence variants from
analysts to clinicians, as well as lead

Downloaded from www.aappublications.org/news by guest on October 10, 2018

Deem

to differential return of results in
clinical practice.

Varying degrees of genetic
literacy among clinicians can also
affect the handling of diagnostic
information from WGS. Clinicians
are not merely passive recipients
of genomic information returned
by analysts but must interpret
how this information will guide
clinical management. They also
must determine ways to translate
and effectively communicate this
information to families making
decisions about care. Although some
clinicians have training in genetics or
genomic medicine, many physicians
feel they are unfamiliar with clinical
applications of genetic technologies
in medical care.46–48 The general
level of genetic literacy among
clinicians in the NICU specifically
is difficult to ascertain. What is
clear is that the rapid advance of
genomic technologies in clinical
care will increasingly demand of
neonatologists a firm grasp of the
risks and benefits of WGS, and an
ability to communicate and tailor
complex, personalized genomic
information to individual families.

It is important for clinicians to
consider how these forms of
informational opacity complicate
their counseling of families in the
NICU. Collective steps can be taken
to correct misinformation that may
impact decision-making about the
care of newborns with disabilities.
To reduce and resolve discrepant
interpretations of sequence variants
between clinical laboratories,
health care professionals and
associations can promote greater
adherence to, and greater cohesion
between, professional guidelines for
standardized reporting of sequence
variants and their interpretation.49
Increased data sharing and
cooperation among laboratories
should also be encouraged. To further
augment genetic literacy within the
NICU, hospitals and clinics might
continue expanding opportunities

to provide genetics and genomic
education through professional
webinars and continuing education
opportunities for staff.50,51

If disability rights advocates who
point to the troubling role uncritical
assumptions about disability play in
the clinic are correct, then it appears
that clinical counseling before
and after WGS can suffer from an
additional source of misinformation.
Whereas informational opacity
will likely dissipate as data sharing
expands across analysts and
clinical laboratories, clinicians can
more directly control the flow of
misinformation from assumptions
about disability and quality of life.
Implicit biases against disability can
impact the manner in which health
care professionals counsel families of
neonates with profound disabilities,
especially in cases in which novel
genetic variants are identified and
no reliable data set on which to
base predictions of phenotypic
expression exists. An important
step toward mitigating the negative
effects of possible bias, even in
these cases, is to consider the extent
to which counseling is informed
by the actual perspectives and
reported experiences of members
of the disability community and
their families. Another worthwhile
measure is to increase direct
interactions between the medical
and disability communities though
the inclusion of disabled persons
or disability rights advocates on
research review boards and hospital
ethics committees.52

It should be noted that there may
be cases in which WGS provides a
definitive, terminal diagnosis for
neonates with profound disability,
and the recommendation of palliative
care to families is appropriate. Even
in these cases, when clinicians strive
to inform the counseling with the
perspectives of disabled persons and
their families, they show respect not
only for the interests and concerns of

the disability community but also for
their patients and their families.

Downstream Effects on Persons
With Disabilities
Because WGS provides rapid,
simultaneous testing of nearly all of
a patient’s genes, clinical WGS will
routinely uncover multiple sequence
variants whose relation to diagnostic
indication is uncertain. In some cases,
clinicians may have sufficient data for
assessing risks for the development
of other diseases or disabilities.
In other cases, findings might be
broadly classified as variants of
unknown significance or as likely
benign, and clinicians accordingly
would not consider them to be
clinically actionable at the time of
sequencing.

Much of the current debate over
the management and reporting of
these incidental findings centers
on questions about the timing
and appropriateness of returning
this information to patients and
research subjects after genomic
sequencing.53–56 With respect to
addressing specific ethical challenges
that incidental findings pose to
acquiring informed consent from
patients or their families, the focus
of clinicians and bioethicists tends
to converge on a common set of
issues. These include the patient’s
or family’s preferences about which
results will be returned, their
understanding of the risks posed by
routine data sharing and storage to
their confidentiality and privacy, and
their attitudes toward future use of
genomic data and recontacting.57–60
But another important consideration,
which has attracted comparatively
less attention in the literature, is how
diagnostic results from WGS could
affect a patient’s access to certain
medical interventions in the future.
These results include definitive or
likely diagnoses, as well as incidental
findings.
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What effects could diagnostic
results from clinical WGS have on
future medical care for persons
with disabilities? Given the novelty
of clinical WGS and the relatively
small sample of cases in which its
implications for future care have
played out, it is difficult to predict
precisely what the downstream
effects will be. But perhaps a
representative example of how
disability presently results in
differential access to medical
interventions can provide some
ground for speculation. Persons
with disabilities are sometimes
viewed as poor candidates for
particular medical interventions.
A familiar example is the denial of
organ transplantation for persons
with certain genetic disorders,
such as trisomy 21 and cystic
fibrosis. Some medical centers view
these persons as poorly suited for
transplantation. Although continual
advances in the medical and social
care of persons with trisomy 21
and cystic fibrosis have led to
longer life expectancies and, in
many cases, greater independence
for persons living with these
conditions, the question of whether
a scarce medical resource such as
a heart or lung should be provided
to persons with these disabilities
remains open among clinicians and
bioethicists.61,62 Clinicians often base
decisions about transplantations
for persons with these disabilities
on objective considerations, such as
the probability of a good outcome
or increased risk of malignancy
associated with certain genetic
conditions. But members of the
disability community may object to
the continuing role that clinicians’
assessments of quality of life or
degree of functional independence
play in determining who will
receive precious medical resources,
particularly if such assessments do
not draw from the perspectives and
experiences of persons and families
living with these conditions.
S52

We might also consider a recent
case report from the Medical College
of Wisconsin that documents how
clinicians together with a family
arrived at a decision against
providing a potentially life-extending
liver transplant to an acutely ill
infant with a diagnosed genetic
disorder.63 The report describes
the detection of TWINKLE gene
mutations through next-generation
sequencing. The infant presented
with fulminant acute liver failure,
and clinical evaluation suggested
mitochondrial DNA (mtDNA)
depletion and possible seizure
activity. Next-generation sequencing
revealed recessive TWINKLE
mutation. Clinicians determined
that long-term prognosis was poor,
given the infant’s mtDNA depletion
and a previously established
association between TWINKLE
mutations and development of
intractable epilepsy in older children
and young adults. In consultation
with the infant’s parents, a decision
against liver transplantation was
reached, and she died of multiorgan
failure and sepsis at 6 months of
age. What remains unclear is how
much weight the clinicians gave
to the probable development of
neurologic deterioration in reaching
this decision. The report states:
“Given the abnormal neurologic
examination and sequence-based
confirmation of a primary mtDNA
depletion disorder and previous
published experience, a decision
was made that [the infant] would
not be an appropriate candidate
for liver transplantation.”Some
may worry that the decision
against transplantation was
reachedlargely on account of the
possibility of development of a
particular neurologic disability,
namely intractable epilepsy, without
consideration of the reported
perspectives of persons living with
that disorder.64 In fairness to the
clinicians, we cannot reasonably
conclude that these perspectives
did not inform the clinicians’ views.

Nor do we have grounds to deny
that the decision resulted from data
about poor outcomes after liver
transplantation in patients who
had other forms mtDNA depletion
accompanied by neurologic
disorder.65 But the report’s omission
of such considerations taking place
might lead some to worry that the
prospect of profound neurologic
disability primarily drove the
decision against transplantation.

Generalizing from these examples,
we can anticipate how diagnostic
information from clinical WGS could
impact future clinical management
for persons with genetic disorders.
It is well known that definitive or
likely diagnosis of genetic disease can
impact present and future clinical
management of acutely ill newborns,
including the potential restriction of
access to scarce medical resources.
But how might incidental findings
that are not related to diagnostic
indications or that are not considered
to be clinically actionable impact
that management? In cases in which
WGS uncovers sequence variants that
are currently associated with later
development of certain disabilities,
similar restriction may be possible.
But this situation may also be true
of cases in which WGS uncovers
variants of unknown clinical
significance. As clinical application
of WGS increases, we can expect
a significant expansion of clinical
genomic databases such as ClinVar
and data sharing between clinical
laboratories. Analysts and clinicians
will likely have wide accessibility
to up-to-date analyses of identified
sequence variants, including
analyses that will potentially result
in future emendations to current
interpretations of the clinical
significance of detected variants.
Some incidental findings presently
classified as variants of unknown
significance might later be associated
with particular disorders or be
considered clinically actionable. That
possibility generates considerable
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uncertainty over how the outcomes
of genomic analyses will play out in
the long term for newborns receiving
WGS.

The potential impact that WGS
will have on a newborn’s future
medical management complicates
the clinician’s task of ensuring
that parental consent for testing
is properly informed. Parental
understanding of how diagnostic
results might impact medical
management is crucial to informed,
responsible decisions about whether
a child should receive WGS. Clinicians
cannot rule out the possibility that
incidental findings will have negative
downstream effects on patients’
future medical care. Insofar as
understanding the potential risks
associated with WGS is a requirement
for consent to be truly informed,
clinicians who recommend WGS for
ill newborns should counsel families
not only about how the genomic
information will be managed but
also about the possibility that this
information will have downstream
effects on their child’s future options
for clinical management. Part of
appropriate clinical counseling,
then, will involve informing parents
that the clinical utility of uncovered
variants may change over time, and
that one implication of this change
could be restriction of their child’s
access to scarce medical resources.
A more robust consent process,
however, will likely have the effect
of slowing the rate of WGS uptake.
But these challenges to acquiring or
approximating informed parental
consent for WGS present an
opportunity for advocates of clinical
WGS to align their interests with
those of disability rights advocates.
Assuming that the uncertainty
surrounding the downstream effects
of WGS will affect WGS uptake,
clinicians who wish to see greater
uptake of WGS in the NICU might
consider advocating for the inclusion
of disability perspectives into
decisions about appropriate medical

interventions and the allocation of
scarce medical resources for persons
with genetic disorders. Before
routine clinical WGS was even on the
horizon, Adrienne Asch suggested
that such advocacy could have wideranging practical implications:
If the disability community correctly
perceives the dominant [social] view to
be one that questions whether a life with
disability can be rich enough to warrant
access to scarce medical resources, then
physicians and bioethicists who become
sensitized to the disability perspective
may do a lot to educate the rest of society
on these issues.34

The voices of clinicians have a
powerful influence on the shaping of
attitudes in the hospital and among
the wider public. Not only might
such advocacy signal to the disability
community that their interests are
being taken seriously by the medical
community, but it also might signal
to parents of acutely ill newborns
that members of the medical
community are working to remove
some obstacles that persons with
disabilities face in gaining access to
certain medical resources.

Concluding Remarks
Clinical WGS promises to enable
swifter diagnosis and improved care
for acutely ill newborns in the NICU.
But, as I suggest in this article, these
are not the only marks according to
which the success of clinical WGS
should be measured. The extent to
which clinicians and bioethicists
attend to the concerns that the
disability community expresses
over the impact of medical genetics
on persons with disabilities will
determine, in part, the success of
WGS programs from practical and
social standpoints.

Attending to these concerns need not
be a limiting factor on the use and
expansion of clinical WGS. By actively
soliciting and compassionately
listening to the real experiences and
perspectives of disabled persons
and their families, clinicians and

bioethicists might rebuild bonds
of trust between the medical and
disability communities. But, perhaps
just as importantly, sensitivity to
these concerns could improve care in
the NICU. Many of the patients who
receive clinical WGS in the NICU have
or will develop profound disabilities.
Awareness of and sensitivity to
the experiences of persons living
with disabilities may help clinicians
provide better individualized care
and more effective counseling to
families of acutely ill newborns who
receive WGS. This, in turn, might
have the effect of furthering the goals
of both advocates of clinical WGS and
disability rights advocates.
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